Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novolin Toronto insulin
- Development stage
- Phase 2
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
Novolin Toronto insulin is a specific formulation of insulin being investigated for intranasal administration. It is designed to deliver insulin to the cerebrospinal fluid and peripheral nervous system, bypassing systemic absorption, to potentially slow the progression of diabetic polyneuropathy (DPN) in individuals with type 1 diabetes. This approach aims to provide therapeutic benefits without significantly affecting systemic blood glucose levels.
- Brand names
- Novolin Toronto
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)
Beyond the preview
Go deeper on Novolin Toronto insulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novolin Toronto insulin.